# Role of IV Calcium to Prevent Diltiazem-related Hypotension

Study · id `cardio:ct-nct06494007` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06494007](<https://clinicaltrials.gov/study/NCT06494007>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06494007

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 217 participants.

## Technical summary

Registry record NCT06494007. Randomized; triple masking; primary purpose prevention. Start 2023-01-01 (actual); primary completion 2024-06-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 217 participants (enrolled count; ClinicalTrials.gov record NCT06494007, source copy `cardio:ctgov-nct06494007-2024-07-11`, retrieved 2026-10-26)
- Started: 2023-01-01 (actual) (ClinicalTrials.gov record NCT06494007, source copy `cardio:ctgov-nct06494007-2024-07-11`, retrieved 2026-10-26)
- Primary completion: 2024-06-01 (actual) (ClinicalTrials.gov record NCT06494007, source copy `cardio:ctgov-nct06494007-2024-07-11`, retrieved 2026-10-26)
- Completion: 2024-07-01 (actual) (ClinicalTrials.gov record NCT06494007, source copy `cardio:ctgov-nct06494007-2024-07-11`, retrieved 2026-10-26)
- Countries: Türkiye (ClinicalTrials.gov record NCT06494007, source copy `cardio:ctgov-nct06494007-2024-07-11`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06494007-2024-07-11`, retrieved 2026-10-26)

## The registry's words

- Brief title: Role of IV Calcium to Prevent Diltiazem-related Hypotension
- Acronym: AFstd
- Condition: Atrial Fibrillation
- Condition: Rapid Ventricular Response
- Condition: Hypotension Drug-Induced
- Intervention (Drug): Sodium chloride
- Intervention (Drug): 90 mg of calcium
- Intervention (Drug): 180 mg Calcium
- Lead sponsor: Haseki Training and Research Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Reducing diltiazem-related hypotension in atrial fibrillation: Role of pretreatment intravenous calcium (`cardio:pubmed-39577214`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 9ece17858f1c7c3e2b15dc0baae286f492a2f3a79d14a97dff9cccb7beb68f64
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
